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Summary 
Objective 
This study aimed to determine how the abilities of the Charlson Index and Elixhauser 
comorbidities compared with the chronic health components of the Acute Physiology and 
Chronic Health Evaluation (APACHE II) to predict in-hospital 30 day mortality among adult 
critically ill patients treated inside and outside of Intensive Care Unit (ICU). 
Methods 
A total of 701 critically ill patients, identified in a prevalence study design on four randomly 
selected days in five acute care hospitals, were followed up from the date of becoming 
critically ill for 30 days or until death, whichever occurred first. Multiple data sources including 
administrative, clinical, pathology, microbiology and laboratory patient records captured the 
presence of acute and chronic illnesses. The exponential, Gompertz, Weibull, and log-logistic 
distributions were assessed as candidate parametric distributions available for the modelling 
of survival data. Of these, the log-logistic distribution provided the best fit and was used to 
construct a series of parametric survival models. 
Results 
Of the 701 patients identified in the initial prevalence study, 637 (90.9%) had complete data 
for all fields used to calculate APACHE II score. Controlling for age, sex and Acute Physiology 
Score (APS), the chronic health components of the APACHE II score, as a group, were better 
predictors of survival than Elixhauser comorbidities and Charlson Index. Of the APACHE II 
chronic health components, only the relatively uncommon conditions of liver failure (3.4%) 
and immunodeficiency (9.6%) were statistically associated with inferior patient survival with 
acceleration factors of 0.35 (95% CI 0.17, 0.72) for liver failure, and 0.42 (95% CI 0.26, 0.72) 
for immunodeficiency. Sensitivity analyses on an imputed dataset that also included the 64 
individuals with imputed APACHE II score showed identical results. 
Conclusion 
Our study suggests that, in acute critical illness, most co-existing comorbidities are not major 
determinants of short-term survival, indicating that observed variations in ICU patient 30-day 
mortality may not be confounded by lack of adjustment to pre-existing comorbidities. 
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Introduction 
The global burden of critical illness is hard to quantify because of the many epidemiological 
challenges in measuring the incidence and prevalence of critical disease. Nonetheless, 
population-based studies suggest a gradual increase in the demand for critical care services 
as the population ages [1]. The brief and often sudden prodrome of critical illness and its 
relatively high short-term mortality add to this challenge. One of the main determinants of 
this short-term survival is the severity of the acute illness [2]. Over the past few decades, 
various scoring systems have been developed to measure the severity of illness among the 
critically ill [3], amongst which, the Acute Physiology and Chronic Health Evaluation (APACHE) 
II remains the most widely used [4-8]. However, patients requiring critical care frequently 
present with multiple physiological abnormalities and are often relatively old [9] with multiple 
chronic comorbid conditions that are not captured by APACHE II [10]. It is unreasonable to 
expect APACHE II to fully account for casemix derived from multiple comorbid conditions [11]. 
The adjustment for the burden of pre-existing comorbid conditions among the critically ill 
remains uncertain [12]. 
Studies that compared the predictive ability of a comorbidity index such as the Charlson Index 
[13-17] or Elixhauser comorbidities [12, 16] with that of the comorbidity components of the 
APACHE II score have produced conflicting results. Some studies found that comorbidities 
significantly improved prognostic information independent of that attained from the chronic 
health points that constitute APACHE II score [12, 14]. Others did not find any significant 
improvement in mortality model discrimination when the Charlson Index or number of 
Elixhauser comorbidities was added to the APACHE II model that did not include its chronic 
components [13, 15, 16]. 
Inconsistencies in the findings of these and other studies may reflect sampling biases, 
confounded by indication [18] or relatively small samples [14], incomplete adjustment for 
comorbidities in studies that used administrative databases [12, 13, 15-17], or single-site 
studies that involved patients that may not have been entirely representative of the critical 
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ill population [13, 14]. Furthermore, critically ill patients who were not treated in intensive 
care units (ICU) were not included in any of the other studies. Such critically ill patients treated 
outside of ICU may have been refused admission to ICU based on age, underlying 
comorbidities, perceived futility due to a high probability of death in spite of admission to ICU 
[19], or due to shortage in ICU beds [20-22]. Female sex as an independent factor associated 
with less admission to intensive or coronary care units has also been reported [23, 24]. 
The main objective of this study, which conducted secondary analyses on prevalence data 
collected in five acute care tertiary hospitals in Israel [20, 25], was to compare the in-hospital 
30-day mortality predictive abilities of the Charlson Index and Elixhauser comorbidities to 
those of the chronic health points of the APACHE II score among adult hospitalised critically 
ill patients. Previous studies targeted the critically ill treated in ICUs. This study targeted all 
critically ill patients treated in all adult hospital departments regardless of whether they were 
admitted to an ICU. Patient data from multiple clinical, administrative, pathology and 
laboratory data sources were utilised to capture acute and chronic illness diagnoses. 
Methods 
Study design and data collection 
Study details have been previously described [20, 25]. In summary, five acute care hospitals 
in Israel volunteered to participate in the original multi-site prevalence study; three of which 
were the largest teaching hospitals in the country. On four randomly selected days, all five 
hospitals were screened to identify critically ill patients in all adult wards. In each of the 
hospitals, on the same days, a team of intensivists, epidemiologists and nurses visited all adult 
hospital beds to identify patients meeting ICU admission criteria (study criteria). These criteria 
were developed by the directors of all ICUs in the country using consensus decision-making 
that was mainly based on, and guided by, the Task Force of the Society of Critical Care 
Medicine [26]. Hospital wards were categorised into three types: (i) intensive care units (ICU) 
which included general and respiratory ICU; (ii) specialised care units that included coronary 
care units, surgical recovery rooms, neurological and medical intensive special care beds; and 
(iii) general / surgical or medical wards that included all adult hospital departments that did 
not have intensive specialised care. All critically ill patients hospitalised within 24 hours 
preceding the screening, including those who died or were transferred to another facility, 
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were eligible to be included in the study. Terminally ill patients with a Do Not Resuscitate 
(DNR) order were not eligible to participate. 
Following the screening process, all information relevant to the study was collected from the 
patients’ medical records, biochemistry and pathology results, microbiological laboratory 
reports, discharge summaries and hospital administrative databases. Information collected 
included: demographics, dates of admission and discharge, date of clinical deterioration, 
acute diagnoses leading to clinical deterioration, presence of infections, all pre-existing 
comorbidities, treating hospital setting, items needed to estimate the Acute Physiology Score 
(APS-12) [2] and APACHE II [2,20], and the simplified Therapeutic Intervention Scoring System 
(TISS-28) [27] that measured intensity of nurse treatment. All-cause 30-day mortality from 
the time the patient became critically ill was also recorded [7, 20, 25]. The chronic health 
points of the APACHE II collected in the original study collated cardiovascular and respiratory 
organ insufficiency as one group; thus, the chronic components included in this study were 
having liver, renal or cardiovascular/respiratory insufficiency and being 
immunocompromised. 
Construction of Charlson Index and Elixhauser co-morbidities 
Using the International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-
CM) coding algorithms, we calculated the Charlson co-morbidity index and defined Elixhauser 
comorbidities [28, 29] based on all comorbid conditions extracted from all data sources. All 
ICD-9-CM codes used to define Charlson and Elixhauser comorbidities are presented in 
Appendices 1 and 2. Charlson Index is based on 17 comorbid conditions, adapted from initial 
19 conditions [30]. Using the original Charlson weights used to construct the final score [30], 
comorbidities were assigned with weights of 1, 2, 3, or 6 depending on the condition, which 
were then summed to form the index. The comorbidities associated with each of these 
weights are presented in Appendix 1. 
Elixhauser comorbidities include a comprehensive set of 31 comorbid conditions [29], 
denoted E1 to E31 (Appendix 2). To avoid consideration of variables with very low numbers of 
events, and to ensure an adequate number of events-per-variable, certain related Elixhauser 
comorbidities were combined into single measures. A variable derived from Elixhauser 
comorbidities i and j is denoted as Ei,j. For power concerns, conditions with very few cases 
(e.g. past history of peptic disease) were not included as separate comorbid categories. 
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Statistical analysis 
All patients were followed from the date of becoming critically ill for 30 days, or until death if 
this occurred before 30 days. Patients who remained alive at the end of the review period 
were so recorded. Deaths within 30 days were recorded including the date of death. Both 
groups of patients in the sample were summarised descriptively. 
The exponential, Gompertz, Weibull, and log-logistic distributions were assessed as candidate 
parametric distributions available for the modelling of survival data, using null models [31]. 
Of these, the log-logistic distribution was deemed the best fitting survival distribution as it 
had the lowest value of the Akaike Information Criteria (AIC) statistic (1090.32, compared to 
1091.52 for Weibull and Gompertz distributions, and 1090.65 for the exponential 
distribution). The log-logistic distribution is parameterised in an accelerated failure time 
metric [32], a general model for survival data in which covariates act multiplicatively on the 
time scale, leading to an interpretation in terms of the speed of progression of terminal illness 
amongst critically ill ICU patients, and allowing for a unimodal hazard function [33]. A series 
of parametric survival models were derived using the selected distribution to determine: 
• the capability of the APS score together with the chronic health points that constitute 
APACHE II score to predict all-cause 30-day patient survival, controlling for sex and age 
(Model 1); 
• whether inclusion of the Charlson index in conjunction with the APS score significantly 
improved predictive capability from that obtained from the APS score and the chronic 
health points alone, controlling for sex and age (Model 2); and 
• whether inclusion of Elixhauser comorbidities in conjunction with the APS score 
significantly improved predictive capability from that obtained from the APS score and 
the chronic health points alone, controlling for sex and age. 
Two models were derived: a full model including all possible comorbidities and a 
parsimonious model including only those comorbidities showing some substantive 
importance (p < 0.2) in the full model (Models 3(a); 3(b)). For each model, p-values and 
acceleration factors (calculated as the exponent of the parameter estimate) with associated 
95% confidence intervals were derived for all included covariates together with the likelihood 
ratio statistic (LRS). 
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Survival curves were generated for patients with key values of components of assessed 
indices appearing to substantively predict survival. Hazard functions for relevant indices were 
also generated as a clinically meaningful measure to increase the understanding of the nature 
of the course of disease for patients of varying conditions. 
Multiple imputation 
Of the 701 patients, 64 (9.1%) had a missing APACHE II score. Little’s test was used to assess 
whether this missing was completely at random (MCAR). The 64 missing APACHE II scores 
were imputed using multiple imputation [34]. The multiple imputation was conducted using 
chained equations using the mi Stata command, with 50 imputed datasets and final estimates 
obtained using Rubin’s rules [35]. 
All analyses were undertaken using Stata statistical software (version 14, Stata-Corp.). 
Ethical considerations 
This study was conducted in accordance with the Declaration of Helsinki. Ethical approval to 
conduct the study was granted by the Israeli Ministry of Health and its Human Research Ethics 
Committee. Because this Ministry of Health, which normally inspects hospitals, conducted the 
initial study, there was a waiver of informed consent based on Israeli law [36]. Furthermore, 
all analyses used non-identifiable data. 
Results 
Descriptive summary of data 
APACHE II scores were available on 637 (90.9%) of the 701 patients included in the original 
study [25]. The 64 patients with a missing APACHE II significantly differed from the remaining 
participants on age, presence of infections, cancer, neurological disorders, TISS scores, and 
the hospital treating ward with a higher probability of being treated in non-ICU general 
medical wards. No substantial group differences were observed in the Charlson index, trauma 
status, sex, most of Elixhauser comorbidities, and 30-day mortality (Table 1). 
Accounting for 30-day mortality, sex, Charlson index, admission due to trauma, and most 
Elixhauser comorbidities (excluding cancer, and neurological disorders), Little’s test showed 
that APACHE II score was missing completely at random (Little’s MCAR test χ2=8.5, p=0.5). 
However, when all other study variables were included, missing of APACHE II score was not 
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at random (Little’s MCAR test χ2=92, p<0.001). These 64 patients were excluded from the 
main analyses. 
<< Please insert Table 1 >> 
Of the included 637 patients, 181 (28.4%) died within 30 days of becoming critically ill (time 
of clinical deterioration). Compared to the survivors, those who died were older (p<0.001) 
with significantly higher Charlson index (p=0.01) and APACHE II score (p<0.001) (Table 2). 
Amongst the 637 patients, 12616 days of patient survival were recorded (average of 19.8 days 
per patient), with deaths being recorded at an incidence of 0.0143 per day. Median death 
rates could not be determined, as deaths did not reach 50% of the cohort during the analysis 
period; 25% of all deaths occurred within 20 days of onset of critical illness. 
<< Please insert table 2>> 
A comparison of characteristics amongst patients who did and did not die during the follow-
up period suggested that the APACHE II chronic health points, APS and Charlson scores, and 
some of the Elixhauser comorbidities, may be likely to be associated with survival, vindicating 
their selection in this analysis. No substantive association existed between survival and the 
TISS score, which was not considered further in this analysis. 
Analysis of model fit 
P-values, acceleration factors and associated 95% confidence intervals (CIs) for all 
factors/covariates in each model are summarised in Table 3, alongside the LRS for each 
model. A model that accounted for age, sex, APS, and the chronic components of the APACHE 
II score, as a group, was a better predictor of survival than Elixhauser comorbidities and 
Charlson Index when sex, age and APS were added to each of the latter. 
<<Please insert Table 3>> 
Survival curves for patients differentiated by the presence or absence of each of the APACHE 
II chronic health points are shown in Figure 1.  All functions are evaluated at mean values of 
other covariates. Among the chronic points of APACHE II, presence or absence of liver 
insufficiency or immunodeficiency were most effective to differentiate between patients in 
terms of survival, however, these conditions accounted for a relatively low proportion of 
patients in the cohort. Of the chronic health points, cardiovascular or respiratory insufficiency 
was observed in the highest proportion of patients (26.6%) but, similar to renal insufficiency, 
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appeared to be less effective in differentiating between patients in terms of short-term 
survival. Incidences of death for patients suffering from each of the chronic health points 
individually ranged from 0.01205 per day (renal insufficiency) to 0.03658 (liver insufficiency). 
Frequencies of patients suffering from two or more of these conditions were in general too 
low to justify generation of incidence rates. 
<<Please insert Figure 1>> 
Charlson scores were recorded in the range from 0 to 6, with the majority of patients having 
an APACHE II score between 10 and 40. Survival graphs plotted for Charlson scores of 0, 2, 4 
and 6 revealed better survival in patients with lower Charlson scores over the full analysis 
period. Incidence rates of deaths ranged from 0.00802 amongst those with Charlson value of 
0 to 0.01776 amongst those with Charlson index value of 6. No significant change in incidence 
of death in patients with non-zero Charlson scores was observed. Only “renal disease” derived 
from the Elixhauser comorbidities was statistically significant or substantively related to 
patient survival in either the full model 3(a) or the parsimonious model 3(b) (Table 3). 
Controlling for age, sex and APS, Elixhauser comorbidities, as a group, were better predictors 
of survival in comparison to the Charlson Index. 
Examination of hazard functions for the APACHE II chronic health points (Figure 2a) showed 
that maximum mortality rate for patients with liver insufficiency occurred after about five 
days. This was later for patients with immunodeficiency. There were minimal changes in the 
lower mortality rates associated with cardiovascular, respiratory or renal failure beyond 
approximately 10 days. The unimodal hazard functions associated with liver failure and 
immunodeficiency arose from the parameterisation of the log-logistic distribution in the 
accelerated failure time metric. Hazard functions for the key Elixhauser comorbidities (Figure 
2b) showed that maximum mortality rate for patients with renal disease occurred at 
approximately five days.  
<<Please insert Figure 2>> 
Sub-analysis on imputed data 
Models 1 and 2 were re-run on an imputed data set as a sensitivity analysis; with all parameter 
estimates revealed to be identical or nearly identical, with negligible difference in the fit of 
10 
 
models derived from the original and imputed data sets. There were no changes in the 
inferences of significance of any parameter between the models run on the two datasets. 
Discussion 
This multisite study compared the abilities of Charlson Index and Elixhauser comorbidities 
with those of the chronic components of APACHE II in predicting 30-day mortality among 
critically ill patients treated inside and outside of intensive care units in five acute care 
hospitals. The key finding was that both Charlson Index and Elixhauser comorbidities were 
inferior predictors of 30-day mortality than the chronic components of APACHE II. 
Additionally, there was no association between the Charlson Index, most of Elixhauser 
comorbidities, and study short-term outcomes in this critically ill population. 
The association of Charlson Index and Elixhauser comorbidities with in-hospital mortality has 
been repeatedly demonstrated [37-39]. However, similar to other studies [13, 16], we found 
that both the Charlson and Elixhauser comorbidity-adjustment methods performed worse 
than APACHE II when predicting short-term mortality in the critically ill. Risk of death among 
patients with various chronic diseases was low and relatively constant over the study period. 
General similarity in survival and hazard curves found for sub-groups of patients over two of 
the APACHE II chronic components and a limited number of Elixhauser conditions suggest that 
both methods are approximately equally effective in predicting survival; however, controlling 
for sex, age and APS, the model which also included the chronic health points of the APACHE 
II index was a better fit to the data than the models which either included the Charlson score, 
or Elixhauser comorbidities. The effect of a small change in the value of the Charlson Index 
was not substantive, showing that this index, which includes 17 comorbid conditions, was not 
associated with short-term survival among the critically ill. Among the chronic components of 
APACHE II, only liver insufficiency and immunodeficiency (both being relatively rare 
conditions) had a significant ability to discriminate between hospital 30-day survivors and 
non-survivors. It is possible that after the critically ill survive past their acute phase illness, 
comorbidities become stronger determinants of long-term survival improving mortality 
prediction over time, as shown in another study that showed that the predictive abilities of 
Charlson Index and Elixahuser comorbidities increased when assessing long-term outcomes 
in the critically ill [40]. 
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Unlike other studies [15-17], this current study captured acute and chronic conditions using 
various data sources that included medical and nursing reports, discharge summaries, 
pathology and microbiological laboratory results, and routinely collected administrative 
hospital data. The sole use of administrative databases, as conducted by most studies that 
compared APACHE II to other comorbidity adjustment methods [12, 13, 15-17], may 
introduce classification biases, and confounding due to the under-coding of comorbidities 
that characterise most routinely collected administrative databases [41]. Critical illness is 
challenging to study with only administrative databases as critical illness is not accurately 
captured by hospital coding [1]. Similarly, such administrative data coding often cannot 
differentiate acute complications from co-existing comorbidities and therefore the predictive 
performance of administrative-data-based co-morbidity may largely depend on the accuracy 
and quality of the routinely collected data [38]. Another strength of this study was the use of 
the log-logistic distribution, parameterised in the accelerated failure time metric, to describe 
short-term survival. This analytic method provided greater flexibility than would be obtained 
by a corresponding distribution parameterised in the proportional hazards metric. 
This study has limitations. Availability of data did not allow the investigation of long-term 
outcomes. Although the inclusion of the critically ill treated inside and outside of ICU was a 
strength in this study, patients who had had a missing APACHE II score were less likely to be 
treated in an ICU. They were also more likely to be younger than those without a missing 
APACHE II score. The younger critically ill patients and those treated outside of ICUs may have 
been under-represented in this study. Nonetheless, the sub-analysis that used multiple 
imputation to estimate the missing APACHE showed that the exclusion of the 9% of patients 
with missing APACHE II had no effect on model findings. 
Conclusions 
In conclusion, this study suggests that, in a population with acute critical illness, adjustment 
for most pre-existing comorbid conditions does not significantly improve 30-day mortality 
prediction. This may indicate that adjusting for APACHE II is sufficient and that observed 
variations in patient short-term mortality may less be confounded by lack of adjustment to 
pre-existing comorbidities. 
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Table 1: Patient characteristics of those with and without missing APACHE II score 
 With APACHE II 
N=637 (90.9%) 
Without APACHE II 
N=64 (9.1%) 
p value 
Age in years, mean (SD) 65.7 (18.2) 59.2 (17.6) 0.006 
Male sex, % 54.0 53.1 0.9 
TISS score day 1^, mean (SD) 
TISS score day 2, mean (SD) 
TISS score day 3, mean (SD) 
TISS score day 4, mean (SD) 
TISS score day 5, mean (SD) 
TISS score day 6, mean (SD) 
26.2 (11.1) 
25.2 (10.8) 
24.2 (11.3) 
23.2 (11.9) 
22.5 (12.6) 
21.7 (12.7) 
14.4 (6.6) 
13.5 (6.4) 
12.3 (6.9) 
10.8 (8.3) 
10.3 (8.5) 
9.1 (7.3) 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Hospital treating ward on day of clinical 
deterioration, % 
Intensive care unit 
Specialised care unit 
General medical ward 
 
 
28.9 
24.5 
46.6 
 
 
3.1 
24.0 
78.1 
 
 
 
 
< 0.001 
Presence of infection on day of clinical 
deterioration, % 
 
37.5 
 
17.2 
 
0.001 
Acquired new hospital infection following clinical 
deterioration, % 
 
48.7 
 
20.3 
 
< 0.001 
Charlson index score, mean (SD) 2.01 (1.7) 2.23 (1.8) 0.3 
Admission due to trauma, % 13.7 10.9 0.5 
Selected Elixhauser comorbidities, % 
Congestive heart failure 
Arrhythmia 
Valvular disease 
Pulmonary circulation disorders 
Peripheral vascular disease 
Hypertension with or without complication 
Paralysis or other neurological disorders 
Chronic pulmonary disease 
Diabetes with or without complications 
Hypothyroidism 
Renal disease 
Liver disease 
Any cancer (solid / blood / metastatic) / AIDS / HIV 
Rheumatoid arthritis / collagen disease 
Coagulopathy 
Anaemia 
 
23.1 
23.6 
10.4 
2.8 
7.5 
32.8 
25.7 
26.2 
7.1 
12.2 
3.0 
1.1 
16.0 
4.9 
7.1 
11.9 
 
12.5 
18.7 
6.2 
1.6 
4.7 
35.9 
10.9 
18.7 
3.1 
10.9 
3.1 
1.6 
31.2 
3.1 
6.2 
12.5 
 
0.052 
0.4 
0.3 
0.6 
0.4 
0.6 
0.009 
0.2 
0.2 
0.8 
0.9 
0.7 
0.002 
0.5 
0.8 
0.9 
30-day mortality, % 28.4 28.1 0.9 
^The simplified Therapeutic Intervention Scoring System (TISS-28) that measured the intensity of nursing 
treatment, was collected on six consecutive days from the day of clinical deterioration 
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Table 2: Patient characteristics by those who did and did not die within 30 days of becoming 
critically ill 
 Survival within 30 days of 
becoming critically ill 
P value 
Characteristics Survived 
N=456 (71.6%) 
Did not survive 
N=181 (28.4%) 
 
Age, mean (SD) 63.0 (18.6) 72.6 (15.1) < 0.001 
Female sex, % 56.1 48.6 0.1 
Charlson Co-morbidity Index, mean (SD) 1.9 (1.7) 2.3 (1.7) 0.01 
APACHE II, mean (SD) 20.6 (7.5) 26.2 (7.3) < 0.001 
APS, mean (SD) 14.9 (7.3) 18.7 (7.3) < 0.001 
TISS, mean (SD) 26.1 (11.1) 26.5 (11.0) 0.7 
 
 
Table 3: P-values, acceleration factors and associated 95% confidence intervals: all models 
Model Covariate p Acceleration 
factor 
95% CI for 
acceleration 
factor 
1 
 
Female sex 0.732 1.053 (0.783, 1.419) 
Age (continuous) <0.001 0.968 (0.957, 0.979) 
APS (continuous) <0.001 0.948 (0.928, 0.969) 
Liver insufficiency 0.004 0.349 (0.170, 0.718) 
Cardiorespiratory insufficiency 0.181 0.788 (0.557, 1.117) 
Renal insufficiency 0.374 1.466 (0.631, 3.410) 
Immunodeficiency 0.001 0.424 (0.258, 0.697) 
LRS=-501.330 
2 Female sex 0.572 1.090 (0.808, 1.470) 
Age (continuous) <0.001 0.971 (0.961, 0.982) 
APS (continuous) <0.001 0.951 (0.932, 0.971) 
Charlson Index (continuous) 0.313 0.955 (0.873, 1.044) 
LRS=-512.263 
3(a) Female sex 0.658 1.071 (0.790, 1.454) 
Age (continuous) <0.001 0.969 (0.958, 0.980) 
APS (continuous) <0.001 0.953 (0.934, 0.973) 
E1 [congestive heart failure] 0.282 0.817 (0.566, 1.180) 
E2 [cardiac arrhythmias] 0.891 1.024 (0.728, 1.442) 
E3 [valvular disease] 0.253 1.360 (0.803, 2.304) 
E4,10 [pulmonary circulation disorders/chronic pulmonary 
disease] 
0.173 1.271 (0.900, 1.794) 
E5 [peripheral vascular disease] 0.232 1.475 (0.780, 2.789) 
E6,7 [hypertension complicated or uncomplicated] 0.197 1.249 (0.891, 1.750) 
E8,9 [paralysis/other neurological disorders] 0.896 1.023 (0.733, 1.433) 
E11,12 [diabetes with or without complications] 0.368 1.289 (0.728, 2.236) 
E13 [hypothyroidism] 0.781 0.939 (0.604, 1.459) 
E14 [renal disease] 0.014 0.391 (0.184, 0.830) 
E15 [liver disease] 0.673 0.737 (0.179, 3.033) 
E17,18,19,20 [cancer solid or metastatic/HIV/AIDS] 0.664 0.918 (0.625, 1.349) 
E21,22,23,24,25 [metabolic disorder] 0.359 0.851 (0.603, 1.201) 
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E26,27 [anaemia] 0.454 1.184 (0.761, 1.840) 
E28,29 [substance abuse] 0.345 0.667 (0.287, 1.547) 
E30,31 [depression/psychosis] 0.745 1.391 (0.197, 10.13) 
LRS=-502.942    
3(b) Female sex 0.628 1.077 (0.798, 1.454) 
Age (continuous) <0.001 0.968 (0.957, 0.978) 
APS (continuous) <0.001 0.952 (0.932, 0.971) 
E4,10 [pulmonary circulation disorders/chronic pulmonary 
disease] 
0.159 1.274 (0.910, 1.784) 
E6,7 [hypertension complicated or uncomplicated] 0.127 1.288 (0.931, 1.781) 
E14 [renal disease]  0.013 0.387 (0.183, 0.816) 
LRS=-506.708 
 
 
 
Figure 1: Survival curves by APACHE II chronic health components 
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Figure 2: Hazards functions for APACHE II chronic health components and key Elixhauser comorbidities 
 
